[ad_1]
Ranked 28th on the KOSPI on the first day of trading with a market capitalization of 12.928.5 billion won
Bullish for share price rise due to abundant growth momentum
SK Bioscience closed the market at 169,000 won, a 160% increase from the public offering price (65,000 won) on the 18th.
SK Biosciences jumped to the upper limit at the same time as the price of the day. Immediately after the opening, the static and dynamic volatility (VI) mitigation device was initiated due to an increase in share prices. Subsequently, the transaction was closed maintaining the intraday ceiling. The market capitalization reached 12,928.5 billion won and jumped to 28th place in KOSPI’s market capitalization.
Furthermore, there are observations that there is a possibility of “exploding” even on the 19th, as the amount of waiting for the purchase continues.
Consequently, the market interest is whether SK Bioscience will continue its upper limit on the 19th. Expert opinions are optimistic.
Kim Ji-ha of the Meritz Securities Research Institute predicted: “Even after listing, the stock price will have great upside potential due to abundant momentum, such as the KOSPI 200 index issue and the announcement of the results of the phase 1 vaccine for a new coronavirus infection (Corona 19) developed by itself.
Han Byeong-hwa, a researcher at Eugene Investment & Securities, said: “The success of SK Bioscience’s self-developed COVID-19 vaccine is very important to increasing corporate value. If commercialized, the pneumococcal vaccine will also be the largest source of revenue after 2025. “
In addition, “Curvec, Novavex and BioEntec, which have grown rapidly thanks to Corona 19, have a current market capitalization of 16 billion to 25 billion won.” He predicted that the share price will form at the same level. “
On the 9th, SK Bioscience, which is considered the prime term for this year’s initial public offering, showed signs of a jackpot, with 14 trillion won rushed on on the 9th, when it began offering public offerings to general investors.
SK Bioscience, which spun off from SK Chemicals in July 2018, is a biopharmaceutical (vaccine) company owned by SK Chemicals with a 98% stake, and is raising a ransom as it emerged particularly as a global vaccine company. It is the only national biological company that has been promoting the development of the Corona 19 vaccine and commissioned joint production, and is conducting clinical trials such as the typhoid, pediatric enteritis, and pneumococcal vaccine. He also handles Consignment Production (CMO) and Consignment Development Production (CDMO) for numerous companies.
In particular, in July last year, AstraZeneca signed a Consignment Production (CMO) contract for Corona 19 vaccine, followed by a NovaVax Development and Production Consignment (CDMO) contract from NovaVax in August. In January this year, a technology from NovaVax was introduced to deliver the Corona 19 vaccine. The rescue skyrocketed when word of it was to be produced, distributed and sold in Korea.
In addition, it will be selected as an independent agency for the task of ‘Establishment and operation of the national distribution management system of Corona 19 vaccines’ of the Korea Centers for Disease Control and Prevention, and will be responsible for the distribution, storage, construction of the cold chain and management of shipments of the Corona 19 vaccine that arrives in Korea.
As of 2019, sales amounted to KRW 183.9 billion and net income was KRW 14.7 billion.
SK Bioscience strongly expressed its intention to accelerate global market entry with funds raised through the listing. SK Bioscience plans to actively secure the R&D platform’s production and technologies from home and abroad while pursuing regional expansion through leadership in vaccines as a medium and long-term growth strategy.
[바이오타임즈=김수진 기자] [email protected]Copyright © BioTimes Unauthorized reproduction and redistribution prohibited
